CONTEXT THERAPEUTICS INC
CNTXNASDAQπ #4638 by market capEarnings Mar 22 Β· PostUS Equity
$0.16βΌ $0.01 (β5.10%)
Market closed Β· at closeTrack CNTX
Get earnings, price moves & breaking news on Telegram
24hβΌ 5.1%
7dβΌ 14.0%
14dβΌ 17.6%
30dβΌ 32.0%
ytdβΌ 89.0%
1yβΌ 85.3%
π¦Market Cap
$15M
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
0.0%
Thin
π΅FCF Margin
0.0%
Thin
βοΈP/S Ratio
0.0x
Cheap
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $0.16 β $0.18
- 52-Week Range
- $0.15 β $3.62
- Volume (shares)
- 1,115,283
- Avg Volume (shares)
- β
- Shares Outstanding
- 91.9M
- Next Earnings
- 2027-03-22
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -0.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.46
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +57.3%
CONTEXT THERAPEUTICS INC
CNTXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$40Mβ² +32.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$26MβΌ β9.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
91.9Mβ² +57.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$66MβΌ β$28M YoY
About CONTEXT THERAPEUTICS INC
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
16 analysts
Strong Buy4
Buy11
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.